Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 16.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,119 shares of the biotechnology company's stock after purchasing an additional 10,391 shares during the quarter. HighTower Advisors LLC's holdings in Exelixis were worth $2,501,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after buying an additional 704,786 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in Exelixis during the 3rd quarter valued at about $14,979,000. Raymond James Financial Inc. acquired a new position in Exelixis in the 4th quarter valued at about $17,046,000. Burney Co. purchased a new stake in Exelixis during the fourth quarter worth about $12,267,000. Finally, Los Angeles Capital Management LLC lifted its position in shares of Exelixis by 20.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company's stock worth $71,828,000 after purchasing an additional 366,141 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Insiders Place Their Bets

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the transaction, the chief financial officer now directly owns 779,607 shares in the company, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Wells Fargo & Company cut Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 price objective on the stock. in a research note on Monday, February 24th. Citigroup lifted their target price on Exelixis from $38.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. BMO Capital Markets lowered Exelixis from an "outperform" rating to a "market perform" rating and increased their price target for the company from $36.00 to $40.00 in a research report on Friday, December 20th. Finally, Stephens reiterated an "equal weight" rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Trading Down 0.0 %

Shares of Exelixis stock traded down $0.01 on Tuesday, hitting $37.71. The stock had a trading volume of 2,520,368 shares, compared to its average volume of 2,087,561. The stock has a market cap of $10.55 billion, a price-to-earnings ratio of 21.31, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The company's 50 day moving average price is $35.70 and its 200 day moving average price is $33.09.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.